Prof. Dr. Jörn Stitz

Dr. phil. nat.
Prof. Dr. Jörn Stitz

Technische Hochschule Köln
Kaiser-Wilhelm-Allee, Gebäude E28
51368 Leverkusen
Raum R 103 Postanschrift


  • Telefon+49 214-32831-4619

Aufgabenbereiche

  • Forschungsgruppen- & Laborleiter "Pharmazeutische Biotechnologie", Projektleiter nach GenTG

Lehrgebiete

  • Molekulare Biologie, B.Sc. Grundlagen Zellbiologie & Biochemie: Zellaufbau, Polymerisation biologischer Makromoleküle und deren Struktur, Genregulation und Signaltransduktionskaskaden, grundlegende Molekularbiologische Methoden
  • Biochemie, B.Sc. Proteinreinigung & -Analyse, Molekularbiologische (PCR, Molekulare Klonierung, DNA-Reinigung) & Mikrobiologische Methoden, Enzymkinetik, Naturstoffe
  • Pharmazeutische und Biotechnologische Mikrobiologie, B.Sc. Virologie, Bakteriologie & Immunologie, Antiinfektiva, Grundlagen: Impfstoffe, Gentherapie, Antikörper
  • Pharmaceutical Biotechnology, M.Sc. Discovery, Development & Production of Biopharmaceuticals: High-Throughput Screening, Evolution Strategies, Production Systems, Up- and Downstream Processing, Biosimilars & Biobetters, Antibodies, Vaccines, Gene Therapy, Act on Genetic Engineering
  • Biologics: From Discovery to Analysis, M.Sc. Biologics Quantification, Assesment of Purity (HCP, HCD), Biologic Acitivity: Cell-Based Assays, FACS
  • Pharmaceutical Cell Technologies, M.Sc. Biologics Drug Discovery & Development - Red Biotech: High-Throughput Screening (HTS) of genetic Libraries, Gene Transfer Technologies, Vector Design, Producer Cell Line Development

Forschungsgebiete

  • Red Biotech - Biologics Drug Discovery & Development High-Throughput Screening (HTS) and Optimization of Gene Therapeutics & Vaccines, monoclonal Antibodies, therapeutic Proteins & Nucleic Acids, Peptides
  • Viral & Transposon Vectors Development for Gene & Immune Therapy, vectored Vaccination, Applications in Biologics Producer Cell Line Establishment
  • VLP Technology Vaccine Development, Display Technology Applications, Antibody Discovery
  • Producer Cell Line Development for Production of Biotherapeutics Upstream Processing (UPS): Non-viral & Viral & Transposon Vector Design, Scale-up, Selection Strategies
  • Downstream Process (DSP) Engineering for Biologics Clarification, Concentration, Polishing: Filtration (Micro- & Ultra- & Tangential Flow), various Methods using Centrifugation, Chromatography, Adsorbersers

+Publikationen

  • Publikationsliste in PubMed
    ab 1997
    J Stitz @ PubMed
  • Patente
    ab 1997
    Publizierte Patent und -Anmeldungen
  • Strategies of keratinocytes and fibroblasts in wound closure observed in an in vitro model.
    S. Kippenberger, F. Görmar, A. Bernd, A. Ramirez, C. Theilig, D. Henrich, J. Stitz, J. Bereiter-Hahn, H. Holzmann, 1995, Hg.: Altmeyer et al. (Eds), Wound Healing and Skin Physiology, Springer-Verlag Berlin & Heidelberg
  • Molecular and virological effects of intracellular anti-Rev single-chain variable fragments on the expression of various Human Immunodeficiency Viruses.
    J. Stitz, 1995, Hg.: AIFO 10 (8), 407-408.
  • Inhibition of HIV-1-replication using an antisense-oligonucleotide.
    J. Stitz, 1996, Hg.: AIFO 11 (4), 183-184.
  • Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells.
    B. Schnierle, J. Stitz, V. Bosch, F. Nocken, H. Merget-Millitzer, M. Engelstädter, R. Kurth, B. Groner, K. Cichutek, 1997, Hg.: Proc. Natl. Acad. Sci. USA 94, 8640-8645.
  • High-titer retroviral pseudotype vectors for specific targeting of human CD4-positive cells.
    J. Stitz, P. Müller, K. Cichutek, 1998, Hg.: Biogenic Amines 14, 407-424.
  • Retroviral cell targeting vectors.
    C. Buchholz, J. Stitz, K. Cichutek, 1999, Hg.: Current Opinions in Molecular Therapeutics 1 (5), 613-621.
  • MLV-derived retroviral vectors selective for CD4-expressing cells and resistant to neutralization by sera from HIV-infected patients.
    J. Stitz, S. Steidl, H. Merget-Millitzer, R. König, P. Müller, F. Nocken, M. Engelstädter, M. Bob-kova, I. Schmitt, R. Kurth, C. Buchholz, K. Cichutek, 2000, Hg.: Virology 267, 229-236.
  • Targeting human T cells by retroviral vectors displaying antibody domains selected from a phage display library.
    M. Engelstädter, M. Bobkova, M. Baier, J. Stitz, N. Holtkamp, T. Chu, R. Kurth, R. Dornburg, C. Buchholz, K. Cichutek, 2000, Hg.: Human Gene Therapy 11, 293-303.
  • Lentiviral vectors pseudotyped with envelope glycoproteins derived from Gibbon Ape Leukemia Virus and Murine Leukemia Virus 10A1.
    J. Stitz, C. Buchholz, M. Engelstädter, W. Uckert, U. Blömer, I. Schmitt, K. Cichutek, 2000, Hg.: Virology 273, 16-20.
  • MLV-derived retroviral pseudotype vectors.
    J. Stitz, C. Buchholz, K. Cichutek, 2000, Hg.: Gene Therapy and Regulation 1 (2), 177-192.
  • A novel vector derived from apathogenic Simian Immunodeficiency Virus.
    J. Stitz, M. D. Mühlebach, U. Blömer, M. Scherr, M. Selbert, P. Wehner, S. Steidl, I. Schmitt, R. König, M. Schweizer, K. Cichutek, 2001, Hg.: Virology 291, 191-197.
  • Targeted gene transfer to lymphocytes using murine leukemia virus vectors pseudotyped with Spleen Necrosis Virus envelope proteins.
    M. Engelstädter, C. J. Buchholz, M. Bobkova, S. Steidl, H. Merget-Millitzer, R. A. Willemsen, J. Stitz, K. Cichutek, 2001, Hg.: Gene Therapy 8, 1202-1206.
  • Coreceptor switch of [MLV(SIVagm)] pseudotype vectors by V3-loop exchange.
    S. Steidl, J. Stitz, I. Schmitt, R. König, E. Flory, M. Schweizer, K. Cichutek, 2002, Hg.: Virology 300, 205-216.
  • Identification of R-peptides in envelope proteins of C-type retroviruses.
    M. Bobkova, J. Stitz, M. Engelstädter, K. Cichutek, C. J. Buchholz, 2002, Hg.: Journal of General Virology 83, 2241-2246.
  • Transduction of MLV-, but not of HIV-1-vectors are pseudotyped-dependent on human T lymphocytes.
    M. D. Mühlebach, I. Schmitt, S. Steidl, J. Stitz, M. Schweizer, T. Blankenstein, K. Cichutek, W. Uckert, 2003, Hg.: Journal of Molecular Medicine 81, 801-810.
  • Genetic engineering of onco/lenti hybrid viruses results in formation of infectious particles, but not of replication-competent viruses.
    S. Steidl, S. Schüle, M. D. Mühlebach, J.Stitz, K. Boller, K. Cichutek, M. Schweizer, 2004, Hg.: Journal of General Virology 85, 665-678.
  • Directed evolution of retrovirus envelope protein cytoplasmic tails guided by functional incorporation into lentivirus particles.
    C. A. Merten, J. Stitz, G. Braun, E. M. Poeschla, K. Cichutek, C. J. Buchholz, 2005, Hg.: Journal of Virology 79, 834-840
  • Retroviral vectors, methods for their preparation and their use for gene transfer into CD4-positive cells
    K. Cichutek, J. Stitz, issued 2005, Hg.: Patent number: 6902929
  • Screening of retroviral cDNA libraries for factors involved in protein phosphorylation in signaling cascades.
    J. Stitz, P. O. Krutzik, G. P. Nolan, 2005, Hg.: Nucleic Acid Research 33, e39
  • Fusoselect: cell-cell fusion activity engineered by directed evolution of a retroviral glycoprotein.
    C. A. Merten, J. Stitz, G. Braun, J. Medvedovska, K. Cichutek, C. J. Buchholz, 2006, Hg.: Nucleic Acid Research 34, e41
  • Maintenance of human T-cell lines and immortalized human B-lymphocytes in chemically defined Hektor minimal media for the production of recombinant proteins and non-recombinant antibodies, respectively.
    R. Eggenschwiler , J. Stitz, 2006, Hg.: Cellculture.com/archives
  • Retroviral vectors for vaccine development: induction of HIV-1-specific humoral and cellular immune responses in Rhesus macaques using a novel MLV(HIV-1) pseudotype vector.
    J. Neumann, J. Stitz, R. Konig, E. Seibold, S. Norley, E. Flory, K. Cichutek, 2006, Hg.: Journal of Biotechnology 124, 615-625
  • Envelope proteins of spleen necrosis virus form infectious human immunodeficiency virus type 1 pseudotype vector particles, but fail to incorporate upon substitution of the cytoplasmic domain with that of Gibbon ape leukemia virus
    J. Stitz, N. Wolfrum, C. J. Buchholz, K. Cichutek, 2006, Hg.: Journal of General Virology 87, 1577-1581
  • IDENTIFICATION OF ANTIGEN OR LIGAND-SPECIFIC BINDING PROTEINS
    U. Grawunder, J. Stitz, issued 2009, Hg.: Application number: 20090226922
  • IDENTIFICATION OF ANTIGEN OR LIGAND-SPECIFIC BINDING PROTEINS
    U. Grawunder, J. Stitz, issued 2012, Hg.: Application number: 20120021491
  • Retroviral Vector Particles and Methods for their Generation and Use
    J. Stitz, issued 2012, Hg.: Application number: 20120258494
  • Retroviral vector particles and methods for their generation and use
    J. Stitz, issued 2014, Hg.: Patent number: 8663989
  • Identification of antigen or ligand-specific binding proteins
    U. Grawunder, J. Stitz, issued 2014, Hg.: Patent number: 8716194
  • Identification of antigen or ligand-specific binding proteins
    U. Grawunder, J. Stitz, issued 2014, Hg.: Patent number: 8748353
  • Retroviral Vector Particles and Methods for their Generation and Use
    J. Stitz, issued 2014, Hg.: Application number: 20140227786
  • Identification of antigen or ligand-specific binding proteins
    U. Grawunder, J. Stitz, issued 2015, Hg.: Application number: 20150072412
  • Antibody Discovery: Development of High-Throughput Screening Platforms
    J. Stitz, 2015, Hg.: Proceedings of the 2015 STEPs Conference, 97-105
  • Retrovirale Vektortechnologie - Eine Toolbox für die Rote Biotechnologie zur Entdeckung, Entwicklung und Produktion von Biologika
    J. Stitz, 2016, Hg.: Pharmind - Die Pharmazeutische Industrie 78 (4), 579-586
  • Herstellung der nächsten Generation viraler Impfstoffe
    S. Barbe & J. Stitz, 2016, TechnoPharm 6, Nr. 6, 312–319 2016
  • Biotechnology – an international business!
    J. Stitz, 2016, BIOspektrum, Nr. 3, 314

+Vorträge

  • Red Biotech – Producing Biologics: Vaccines
    The Colors of Biotechnology, Red Biotechnology Products & Compounds, Public Health & Sustainability, Vaccines: Scientific Background, Examples, Vaccine Platforms, From Discovery to Market Entrance Examples, Pros and Cons
    2015
    Scientific Lectures at STEPs
  • Development of high-throughput screening platforms for antibody discovery
    Antibody Discovery Techniques Today and Tomorrow: Strengths and Limitations of current Technologies; Invention of Advanced new Discovery Technologies
    2015
    Wissenschaftliches Symposium des Forschungsinstituts STEPS
  • Novel Antibody Discovery Technologies
    Jörn Stitz and colleagues presented on a novel innovative platforms for antibody discovery.
    2009
    European Congress of Immunology - ECI
  • Onco-retroviral and lentiviral vectors as tool for research in virology, vaccine development and somatic gene therapy
    Retroviral vectors are frequently used in somatic gene therapy trials. Moreover, such vectors allow the detailed examination of isolated events of the interaction of host cell and virus. Viral vectors have also excellerated research in molecular biology and the development vaccines.
    2005
    Heinrich-Pette-Institut Activity Report 2005/2006
  • Retroviral Pseudotype and Cell Targeting Vectors
    J. Stitz presented on behalf of the research group of Prof. Dr. Cichutek at the Paul-Ehrlich-Institute on the latest progress in developing pseudtotype vectors allowing for selective gene transfer into relevant target cell types for future applications in gene therapy.
    1998
    Cold Spring Harbor Laboratory

+Mitgliedschaften

  • European Biotechnology Network
    The primary goal of the European Biotechnology Network is to improve cooperation in the fields of biotechnology and the other life sciences, primarily between the 28 member states of the European Union, Switzerland and Norway. Biotech professionals from science and research, industry, academia, organisations or state agencies and authorities are invited to become involved in the network and make use of the services it provides.
    European Biotechnology Network website
  • BIO.NRW.red
    BIO.NRW, als eines der 16 Landescluster, katalysiert zentral die nachhaltige Entwicklung der Stärken der nordrhein-westfälischen Roten Biotechnologie.
    BIO.NRW.red
  • Gesellschaft für Virologie e.V.
    Die GfV verfolgt das Ziel einer Förderung der Virologie auf allen Fachgebieten durch Vermehrung und Austausch von Wissen auf dem Gebiet der virologischen Forschung, vor allem im deutschsprachigen Raum. Dies soll unter anderem erreicht werden durch wissenschaftliche Tagungen, Förderung des Publikationswesens und Zusammenarbeit mit anderen wissenschaftlichen Gesellschaften. Die Gesellschaft fördert akademische Lehre und Ausbildung sowie fachliche Fortbildung. Sie bietet Trägern wissenschaftlicher Einrichtungen, forschungsfördernden Organisationen und Gremien von Politik und Gesellschaft beratende Dienste an, soweit wissenschaftliche Aspekte der Virologie, die akademische Ausbildung und fachliche Fortbildung berührt werden.
    GfV
  • Forschungsinstitut STEPS
    Das Instituts STEPS (Sustainable Technologies and Computational Services for Environmental and Production Processes) entwickelt nachhaltige Verfahren und informationstechnische Dienste für Umwelt und Produktion.
    STEPS
  • BioRiver - Life Science im Rheinland e.V.
    Branchenverband für die Biotechnologie in Rheinland
    BioRiver

+Auszeichnungen

  • "summa cum laude"
    Doktortitel phil. nat. im Fachbereich Biochemie der Goethe Universität in Frankfurt am Main
  • European Molecular Biology Organization (EMBO) Fellowship
    EMBO Long-term Fellow von 2002 bis 2005 im Labor von Prof. Dr. Garry P Nolan, Stanford University, USA: "Disruption and characterization of intracellular signaling cascades involved in angiogenesis"
    Nolan Lab @ Stanford University
  • Finalst GO-Bio 2007: „Entwicklung zelltyp-spezifischer retroviraler Vektoren zur Verwendung in der Genmarkierung und in „high-throughput screens“ zur Identifizierung von Zelloberflächenproteinen und deren Liganden“
    GO-Bio ist eine Firmengründungsoffensive im Feld Biotechnologie vom Bundesministerium für Bildung und Forschung (BMBF)
    GO-Bio @ BMBF

+Lebenslauf

2014 - today Professor Pharmaceutical Biotechnology
Cologne University of Applied Sciences J Stitz @ FH-Köln
2011 - 2013 Research Group Leader
VLP Technology, Dept. Viral Vaccine Discovery and Translational Medicine, Crucell / Janssen Pharmaceuticals, NL Crucell @ Janssen Pharmaceuticals
2010 - 2011 Senior Scientist
Antibody Discovery Technologies, Innovation Team, Crucell, NL Crucell @ Janssen Pharmaceuticals
2007 - 2010 Research Group Leader
Antibody Library Screening & Retrovirus Technology, 4-Antibody AG, CH 4-Antibody @ Agenusbio
2005 - 2007 Junior Group Leader
ETH Zürich, CH: Dept. Bio-Engineering ETH Zürich website
2004 - 2005 Senior Scientist
Stanford University, USA: Garry P Nolan Lab Dept. Genetic Pharmacology, Immunology & Microbiology Nolan Lab @ Stanford University
2002 - 2004 EMBO-Fellow
Stanford University, USA: Garry P Nolan Lab Dept. Genetic Pharmacology, Immunology & Microbiology J Stitz @ Nolan Lab
1998 - 2002 Postdoctoral Fellow
Paul-Ehrlich-Institute (PEI), D: Dept. Medical Biotechnology Research @ PEI
1995 - 1998 Ph.D. Student
Paul-Ehrlich-Institute (PEI), D: Dept. Medical Biotechnology
1989 - 1994 Student - Master of Science in Biology
Goethe University, Frankfurt am Main, Germany
M
M